Jim Simons Inhibrx, Inc. Transaction History

Renaissance Technologies LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2023 Aug 11, 2023	SELL	$16.96 - $27.82 $2.06 Million - $3.37 Million	-121,200 Reduced 56.77%	92,300 $2.4 Million
Q1 2023 May 12, 2023	BUY	$18.45 - $27.14 $3.94 Million - $5.79 Million	213,500 New	213,500 $4.03 Million

132

35.5M

64.8K

91.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.